Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA

Phase 2

Terminated

Conditions: Alopecia Areata

Interventions: Drug: PF-06651600
Drug: Placebo

First Posted Date: 2020-08-18

Last Posted Date: 2024-06-18

Lead Sponsor: Pfizer

Target Recruit Count: 71

Registration Number: NCT04517864

Locations: 🇺🇸
Stony Brook Dermatology, Stony Brook, New York, United States
🇨🇦
Lynderm Research Inc., Markham, Ontario, Canada
🇺🇸
Marvel Clinical Research 002, LLC, Huntington Beach, California, United States

and more 36 locations

A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70)

Phase 2

Completed

Conditions: Hyperlipidemias
Dyslipidemias
Hyperlipoproteinemias

Interventions: Drug: Placebo
Drug: Vupanorsen

First Posted Date: 2020-08-18

Last Posted Date: 2022-10-04

Lead Sponsor: Pfizer

Target Recruit Count: 286

Registration Number: NCT04516291

Locations: 🇺🇸
Horizon Clinical Research Associates, PLLC, Gilbert, Arizona, United States
🇨🇦
GNMI MRI and CT Medical Imaging, Mississauga, Ontario, Canada
🇨🇦
Aggarwal and Associates Limited, Brampton, Ontario, Canada

and more 109 locations

Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations

Phase 4

Completed

Conditions: Metastatic Non Small Cell Lung Cancer

Interventions: Drug: Dacomitinib

First Posted Date: 2020-08-13

Last Posted Date: 2024-04-05

Lead Sponsor: Pfizer

Target Recruit Count: 101

Registration Number: NCT04511533

Locations: 🇮🇳
Artemis hospital, Gurugram, Haryana, India
🇮🇳
Apex Wellness Hospital, Nashik, Maharashtra, India
🇮🇳
Gujarat Hospital - Gastro & Vascular Centre, Surat, Gujarat, India

and more 12 locations

Study To Evaluate The Impact Of Early Initiation Of Biological Treatment With Ankylosing Spondylitis

Completed

Conditions: Ankylosing Spondylitis

Interventions: Drug: Etanercept

First Posted Date: 2020-08-11

Last Posted Date: 2021-10-28

Lead Sponsor: Pfizer

Target Recruit Count: 763

Registration Number: NCT04507763

Locations: 🇮🇶
Pfizer, Baghdad, Iraq

Study To Evaluate The Efficacy And Long-Term Adherence Of Spondyloarthropathies(SpA) Patients On Enbrel

Completed

Conditions: Spondyloarthrosis

Interventions: Drug: Etanercept

First Posted Date: 2020-08-11

Last Posted Date: 2021-10-04

Lead Sponsor: Pfizer

Target Recruit Count: 763

Registration Number: NCT04507776

Locations: 🇮🇶
Pfizer, Baghdad, Iraq

A Study of the Long-Term Safety of Crisaborole Ointment, 2% in Japanese Pediatric and Adult Participants With Mild to Moderate Atopic Dermatitis

Phase 3

Terminated

Conditions: Atopic Dermatitis

Interventions: Drug: Crisaborole 2%

First Posted Date: 2020-08-04

Last Posted Date: 2021-08-12

Lead Sponsor: Pfizer

Target Recruit Count: 40

Registration Number: NCT04498403

Locations: 🇯🇵
Mildix Skin Clinic, Adachi-ku, Tokyo, Japan
🇯🇵
Sugamo Kobayashi Derma Clinic, Toshima-Ku, Tokyo, Japan
🇯🇵
Takagi Dermatological Clinic, Obihiro, Hokkaido, Japan

and more 8 locations

TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.

Completed

Conditions: Breast Cancer

First Posted Date: 2020-08-04

Last Posted Date: 2020-08-04

Lead Sponsor: Pfizer

Target Recruit Count: 1

Registration Number: NCT04498481

Locations: 🇺🇸
Pfizer United States, New York, New York, United States

Study To Characterize Mass Balance, Absolute Bioavailability, Fraction Absorbed And Pharmacokinetics Of 14C PF-06882961

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: [14C]PF-06882961, 50 mg
Drug: PF-06882961, 50 mg and [14C]PF-06882961, 100 ug

First Posted Date: 2020-07-31

Last Posted Date: 2020-11-25

Lead Sponsor: Pfizer

Target Recruit Count: 6

Registration Number: NCT04495140

Locations: 🇳🇱
PRA Health Sciences, Groningen, Netherlands
🇳🇱
PRA Health Sciences Utrecht, Utrecht, Netherlands

Pharmacokinetic Study of Aztreonam-Avibactam in Severe Renal Impairment

Phase 1

Completed

Conditions: Renal Insufficiency

Interventions: Drug: Aztreonam-Avibactam

First Posted Date: 2020-07-24

Last Posted Date: 2023-07-28

Lead Sponsor: Pfizer

Target Recruit Count: 11

Registration Number: NCT04486625

Locations: 🇺🇸
Prism Research LLC dba Nucleus Network, Saint Paul, Minnesota, United States

BIOEQUIVALENCE STUDY IN HEALTHY PARTICIPANTS COMPARING 4 MG AND 8 MG FESOTERODINE EXTENDED-RELEASE TABLETS (TOVIAZ™), MANUFACTURED AT ZWICKAU VERSUS FREIBURG

Phase 1

Completed

Conditions: Neurogenic Detrusor Overactivity

Interventions: Drug: 4 mg Fesoterodine ER tablet from Zwickau
Drug: 4 mg fesoterodine ER tablet from Freiburg
Drug: 8 mg fesoterodine ER tablet from Zwickau
Drug: 8 mg fesoterodine ER tablet from Freiburg

First Posted Date: 2020-07-20

Last Posted Date: 2021-05-07

Lead Sponsor: Pfizer

Target Recruit Count: 18

Registration Number: NCT04478357

Locations: 🇧🇪
Brussels Clinical Research Unit, Brussels, Bruxelles-capitale, Région DE, Belgium

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy